Alvotech Publishes 2025 Annual Report
Alvotech (NASDAQ: ALVO) published its 2025 Annual Report on March 30, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Alvotech (NASDAQ: ALVO) published its 2025 Annual Report on March 30, 2026. The report is available in the company's investor relations website and is attached to the announcement in PDF and iXBRL formats. Contact details for media and investors are provided for further inquiries.
Details
News Market Reaction – ALVO
On Mar 31, the first trading day after this news, ALVO closed 4.26% above the previous close.
Data tracked by StockTitan Argus for the Mar 31 session.
Historical Context
-
Strong Q4 and FY 2025 revenue and EBITDA with reaffirmed 2026 guidance.
-
Announcement of date and time for Q4 and FY 2025 earnings release.
-
Intra‑group transfer of 2,701,617 shares within Aztiq-related entities.
-
Capital increase via 12,500,000 new shares to subsidiary for obligations.
-
Pivotal PK study for AVT80 met all primary endpoints vs Entyvio.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
ixbrl technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
REYKJAVIK, ICELAND (March 30, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”) has published its Annual Report for 2025. The report is available in the investor relations section of Alvotech’s website at: https://investors.alvotech.com/financials and is attached to this announcement in PDF and iXBRL formats.
For further information, contact:
Media
Benedikt Stefansson
Sarah MacLeod
alvotech.media@alvotech.com
Investors
Dr. Balaji V Prasad (US)
Patrik Ling (SE)
Benedikt Stefansson (IS)
alvotech.ir@alvotech.com
About Alvotech
Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in biosimilars by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira® (adalimumab), Stelara® (ustekinumab), Simponi® (golimumab), Eylea® (aflibercept) and Prolia®/Xgeva® (denosumab). The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. For more information, please visit https://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.
For more information, please visit our investor portal, and our website or follow us on social media on LinkedIn, Facebook, Instagram and YouTube.
Attachments
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.